Pharmaceutical Executive July 29, 2024
The company plans to develop these treatments using it’s AI-powered platform.
ReviR Therapeutics announced that it has secured $30 million in Series A financing, which will be used to augment the company’s AI-powered drug discovery platform. The platform, VoyageR, will be identify potential new treatments for conditions like Huntington’s Disease, Chorcot-Marie-Tooth disease, and ALS.
ReviR’s strategy is focused on developing orally administered genetic therapies, which greatly reduces the burden of treatment on the actual patient. To achieve this, the company is focused on developing RNA therapies, which can be used to treat so-called un-druggable disease-related proteins.
In a press release, ReviR Therapeutics co-founder and CEO Dr. Peng Yue said, “Neurological diseases affect a large number of individuals worldwide, many of...
Today's Sponsors
Today's Sponsor